Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure | Zendy

Kim Fox | Zendy; Ian Ford | Zendy; Philippe Gabríel Steg | Zendy; JeanClaude Tardif | Zendy; Michał Tendera | Zendy; Roberto Ferrari | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure

Author(s) -

Kim Fox,

Ian Ford,

Philippe Gabríel Steg,

JeanClaude Tardif,

Michał Tendera,

Roberto Ferrari

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1406430

Subject(s) - ivabradine , medicine , cardiology , heart failure , myocardial infarction , heart rate , placebo , coronary artery disease , hazard ratio , angina , clinical endpoint , confidence interval , randomized controlled trial , blood pressure , alternative medicine , pathology

An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 beats per minute or more.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research